4,916 Merck & Co., Inc. $MRK Shares Sold by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 103,510 shares of the company’s stock after selling 4,916 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $15,041,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Horizons Wealth Management acquired a new stake in Merck & Co., Inc. in the 3rd quarter valued at approximately $30,000. Bullseye Investment Management LLC bought a new position in Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Graney & King LLC lifted its holdings in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $41,000. Finally, Evergreen Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the first quarter worth approximately $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This represents a 24.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Maraldo sold 18,706 shares of the stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last ninety days. 0.17% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MRK shares. Cantor Fitzgerald increased their price objective on Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Argus boosted their target price on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Royal Bank Of Canada dropped their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating on the stock in a research report on Monday, October 12th. TD Cowen upped their target price on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a research note on Wednesday, September 23rd. Finally, Guggenheim increased their price target on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $146.01 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market cap of $360.22 billion, a price-to-earnings ratio of 116.81, a P/E/G ratio of 6.71 and a beta of 0.21. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The stock’s fifty day simple moving average is $145.60 and its 200 day simple moving average is $129.24.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter last year, the business posted $2.13 earnings per share. The company’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts expect that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.